Severe forms of pulmonary arterial hypertension (PAH) are characterized by various
degrees of remodeling of the pulmonary arterial vessels, which increases the pulmonary …

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right
heart failure and ultimately death if untreated. The first classification of PH was proposed in …

Background Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic
guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate …

Progression of pulmonary hypertension is associated with increased proliferation and
migration of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and …

In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has
evolved from a potential anti-angina drug to an on-demand oral treatment for erectile …

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors,
roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3, 5-di-chloropyrid-4-yl]-benzamide) …

Rationale: Phosphodiesterase Type 5 (PDE5) inhibition represents a novel strategy for the
treatment of pulmonary hypertension. Objectives: Our aim was to establish the distribution of …

Pulmonary hypertension (PH) is a disorder that develops as a result of remodeling of the
pulmonary vasculature and is characterized by narrowing/obliteration of small pulmonary …

Pulmonary hypertension (PH) is a serious disease characterized by various degrees of
pulmonary vasoconstriction and progressive fibroproliferative remodeling and inflammation …

Background: Alveolar hypoxia causes pulmonary hypertension and enhanced right
ventricular afterload, which may impair exercise tolerance. The phosphodiesterase-5 …